HER2 Support Group Forums - View Single Post

agness · 09-11-2015, 11:37 AM

IRSA - Stereotactic Radiosurgery for Patients with Metastatic Brain Cancer
http://www.irsa.org/metastatic%20guideline.pdf

[May 2008, the latest version I could find]

"Lesions of the brain and leptomeninges account for 80% of intracranial metastases. The majority of brain metastases (approximately 80%) are located in the cerebral hemispheres. The cerebellum (10–15%) and brainstem (2– 3%) are less frequently involved."

"Patients treated with conventional open surgical resection without WBRT had a 46% risk of failure at the site of the resection in a randomized trial evaluating the role of WBRT after surgical resection. In subsequent studies patients were treated with SRS alone (without WBRT). These studies found excellent local control (70–80% at one year). Other published series of patients treated with SRS have demonstrated a risk of distant brain failure at one year, ranging from 43% to 57%. In general, the risk of new metastasis in patients with solitary tumors is approximately 37% (crude), but the actuarial risk is 50% at one year"

09-11-2015, 11:37 AM	#8
agness Senior Member Join Date: Aug 2014 Location: Seattle, WA Posts: 285	Re: Compiling Data on HER2 Brain Mets IRSA - Stereotactic Radiosurgery for Patients with Metastatic Brain Cancer http://www.irsa.org/metastatic%20guideline.pdf [May 2008, the latest version I could find] "Lesions of the brain and leptomeninges account for 80% of intracranial metastases. The majority of brain metastases (approximately 80%) are located in the cerebral hemispheres. The cerebellum (10–15%) and brainstem (2– 3%) are less frequently involved." "Patients treated with conventional open surgical resection without WBRT had a 46% risk of failure at the site of the resection in a randomized trial evaluating the role of WBRT after surgical resection. In subsequent studies patients were treated with SRS alone (without WBRT). These studies found excellent local control (70–80% at one year). Other published series of patients treated with SRS have demonstrated a risk of distant brain failure at one year, ranging from 43% to 57%. In general, the risk of new metastasis in patients with solitary tumors is approximately 37% (crude), but the actuarial risk is 50% at one year" __________________ Dx 2/14 3b HER2+/HR- left breast, left axilla, internal mammary node (behind breast bone). Neoadjuvant TCHP 3/14-7/2. PCR 8/14 LX and SND. 10/21-12/9 Proton therapy to chest wall. Dx 7/20/15 cerebellar met 3.5x5cm HER2+/HR-/GATA3+ 7/23/15 Craniotomy. 7/29/15 bone scan clear. 8/3/15 PET clean scan. LINAC SRS (5 fractions) Sept 2015. 9/17/15 CSF NED, 9/24/15 CSF NED, 11/2/15 CSF NED. 10/27/15 atypical uptake in right cerebellum - inflammation? 12/1/15 Leptomeningeal dx. Starting IT Herceptin. 1/16 - 16 fractions of tomotherapy to cerebellum, break of IT Herceptin during rads, resume at 100 mg weekly 3/2016 - stable scan 5/2016 stable scan 7/2016 pseudoprogression? 9/2016 more LM, start new chemo protocol and IV therapy treatment with HBOT 11/2016 Cyberknife to temporal lobe, HBOT just prior 12/2016 - lesions starting to show shrinkage 8/2017 - Stable since Dec 2016. Temporal lobe lesion gone. Using TCM, naturopathic oncology, physical therapy, chiro, massage, medical qigong, and energetic healing modalities in tandem. Stops at nothing. Mother of 2 boys - ages 7 and 10 (8/2017) and a lovely partner with lots to live for.